logo-loader

Horizon Discovery strikes new licensing deal for bioproduction lines

Published: 07:44 19 Oct 2016 BST

cell under microscope
"Horizon continues to be a disruptive influence in the bioproduction arena....," said its chief executive

Horizon Discovery Group PLC (LON:HZD) has struck a subscription licensing deal with an unnamed partner, the first of its kind, for its bioproduction cell lines worth at least £500,000.

The gene editing specialist said the partner will be given immediate access to Horizon's cutting-edge Null CHO K1 bioproduction cell line  indefinitely for use in making new drugs.

The CHO SOURCE platform delivers a fully engineered and characterised host cell line, ideally suited to the manufacture of recombinant protein therapeutics.

The commercial group will also be able to access Horizon's programme of continuous cell line innovation, enabling them to license, via the subscription, any follow-on cell lines developed as part of the program at a 50% discount within five years.

The minimum fee will be paid up front, with a significant amount to be recognised in full year 2016, Horizon said.

Horizon's chief executive Dr Darrin Disley told investors: "Horizon continues to be a disruptive influence in the bioproduction arena, using technical and commercial innovation to accelerate advancements in drug manufacturing.

"This new announcement further validates our approach, with our partner demonstrating their confidence by making a five year commitment via subscription model to the program. We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space."

Today's deal follows a lengthy evaluation period started in the fourth quarter of 2015 and underlines the confidence in the partner that Horizon will provide a number of additional cell lines over the next five years, leading to significant efficiency improvements in their biomanufacturing capability. 

Acquisition gives Horizon Discovery a 'full and complete suite of tools' to...

Chris Claxton, VP Investor Relations & Corporate Communications at Horizon Discovery Group PLC (LON:HZD), discusses with Proactive their 'transformational' acquisition of GE healthcare business Dharmacon. The US$85mln deal was announced in July and funded through cash and shares and...

on 4/9/17